Selected Antihypertensive Agents and Their Fixed-Dose Combinations Effectively Ameliorate Trastuzumab-Mediated Cardiac Dysfunction In Rats
الملخص
This study evaluates the therapeutic potentials of selected antihypertensive drugs [valsartan, amlodipine, lisinopril and their fixed-dose combinations (amlodipine + lisinopril) and (valsartan + lisinopril)] in ameliorating trastuzumab (TZM)‑induced cardiac dysfunctions in experimental rats. After an ethical clearance for the study was obtained, in-bred young adult female Wistar rats were randomly allotted into 10 groups of 6 rats per group. Group I rats were treated with 10 ml/kg/day sterile water p.o. and 1 ml/kg/day sterile water i.p.; Group II, III and IV rats were orally treated with 5 mg/kg/day VAL and 1 ml/kg/day sterile water i.p., 0.25 mg/kg/day ADP and 1 ml/kg/day sterile water i.p., 0.035 mg/kg/day LSP and 1 ml/kg/day sterile water i.p., respectively. Group V rats were orally pretreated with 10 ml/kg/day of sterile water before i.p. 2.25 mg/kg/day of TZM. Groups VI-VIII rats were equally pretreated with 5 mg/kg/day VAL, 0.25 mg/kg/day ADP, and 0.035 mg/kg/day LSP before i.p. 2.25 mg/kg/day TZM treatment, respectively. Also, Groups IX and X rats were orally pretreated with the fixed-dose combinations of 0.25 mg/kg/day ADP + 0.035 mg/kg/day LSP in dissolved in sterile water and 5 mg/kg/day VAL + 0.035 mg/kg/day LSP before 2.25 mg/kg/day TZM treatment for 7 days. Blood pressure parameters [systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial blood pressure (MAP)] and electrocardiogram (ECG) of the treated rats were measured using non-invasive procedures on days 1 and 7 of the experiment, following which the treated rats were sacrificed humanely under light inhaled diethyl ether and histopathological examination was conducted on all treated rat hearts. Results show that repeated TZM treatment significantly (p<0.05) raised SBP, DBP and MAP values from 115.0 ± 17.1 mmHg, 85.1 ± 15.1 mmHg and 94.7 ± 15.5 mmHg, respectively on day 1 to 127.7 ± 27.8 mmHg, 87.4 ± 27.3 mmHg and 100.5 ± 26.4 mmHg, respectively, on day 7. Oral pretreatments with VAL, ADP, LSP and their fixed-dose combinations significantly (p<0.05) attenuated increases in the SBP, DBP and MAP values with the most significant attenuation mediated by the fixed-dose VAL + LSP combination at the SBP, DBP and MAP values of 103.8 ± 20.6 mmHg, 65.5 ± 18.8 mmHg, and 77.9 ± 18.7 mmHg, respectively. TZM treatment also profoundly (p<0.05) prolonged the QT and corrected QT intervals from 85.0 ± 11.5 ms and 161.6 ± 20.3 ms, respectively, on day 1 to 110.2 ± 21.5 ms and 226.5 ± 41.5 ms, respectively, on day 7. However, these QT and corrected QT interval prolongations were effectively and profoundly attenuated by oral pretreatments with VAL, ADP, LSP and their fixed-dose combinations. In addition, TZM cardiotoxicity was characterized by marked vascular and cardiomyocyte congestion and coronary artery microthrombi formation. However, these histopathological changes were reversed with oral pretreatments with ADP, LSP, VAL and fixed-dosed [(ADP + LSP) and (VAL + LSP)] combinations although fixed-dose VAL + LSP was associated with histopathological lesions of coronary arterial wall cartilaginous metaplasia. Overall, this study revealed the promising therapeutic potentials of VAL, ADP, LSP and their fixed-dose combinations as repurposed drugs for the prevention of TZM-mediated cardiac dysfunctions
المراجع
Adedapo, A., Babarinsa, O., Oyagbemi, A., et al. (2016). Cardiotoxicity study of the aqueous extract of corn silk in rats. Macedonian Veterinary Review 39 (1): 43-49.
Akinde, O.R., Phillips, A.A., Oguntunde, O.A., et al. (2015). Cancer mortality pattern in Lagos University Teaching Hospital, Lagos, Nigeria. Journal of Cancer Epidemiology 2015: Article ID 842032; https://doi.org/10.1155/2015/842032
Akolkar, G., Bhullar, N., Bews, H., et al. (2015). The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity. Cardiovascular Ultrasound 13: 18.
Albrecht, M., Henke, J., Tacke, S., et al. (2014). Effects of isoflurane, ketamine-xylazine and a combination of medetomidine, midazolam and fentanyl on physiological variables continuously measured by telemetry in Wistar rats. BMC Veterinary Research 10: 198. https://doi.org/10.1186/s12917-014-0198-3
Blackwell, K.L., Burstein, H.J., Storniolo, A.M., et al. (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of Clinical Oncology 28: 1124-1130.
Blanter, J.B., Frishman, W.H. (2019). The preventive role of angiotensin converting enzyme inhibitors/angiotensin-II receptor blockers and beta-adrenergic blockers in anthracycline- and trastuzumab induced cardiotoxicity. Cardiology Reviews 27(5): 256259; https://doi.org/10.1097/CRD.0000000000000252
Boekhout, A.H., Gietema, J.A., Milojkovic Kerklaan, B., et al. (2016). Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncology 2(8): 1030-1037; https://doi.org/10.1001/jamaoncol.2016.1726
Boonman-de Winter, L.J.M., Rutten, F.H., Cramer, M.J., et al. (2015). Efficiently screening heart failure in patients with type 2 diabetes. European Journal of Heart Failure 17: 187-195.
Brown, S-A., Okwuosa, T.M., Barac, A., et al. (2020). The role of angiotensin converting enzyme inhibitors and β-blockers in primary prevention of cardiac dysfunction in breast cancer patients. JAHA 2020: 9; https://doi.org/10.111/JAHA.119.01327
Carreon, C.K., Sanders, S.P., Ashworth, M.T. (2020). Chondroid and osseous metaplasia of the
central fibrous body in adolescent hearts with mutations in TNNI3 and TNNT2 genes. Pediatric and Development Pathology; https://doi.org/10.1177/1093526620937572
Chen, M.F., Manson, D.K., Yuan, A., et al. (2020). Trastuzumab-induced cardiotoxicity and hypertension among racially and ethnically diverse patients with HER2-positive early-stage breast cancer. Journal of Clinical Oncology 38(15Suppl.): e24092; https://www.doi.org/10.1200/JCO.2020.38.15_suppl.e24092
Costa, R.L.B., Czerniecki, B.J. (2020). Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. Npj Breast Cancer 6: 10 (2020); https://doi.org/10.1038/s41523-020-0153-3
Drebin, J.A., Stern, D.F., Link, V.C., et al. (1984). Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature 312(5994): 545-548
Eiger, D., Franzoi, M.A., Pondé, N., et al. (2020). Cardiotoxicity of trastuzumab given for 12
months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. ESMO Open 5: e000659.
ElZarrad, M.K., Mukhopadhyay, P., Mohan, N., et al. (2013) Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS One 8(11): e79543; https://www.doi.org/10.1371/journal.pone.0079543
Fang, K., Zhang, Y., Liu, W., et al. (2020). Effects of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a meta-analysis of randomized controlled trials. Heart Failure Reviews https://www.doi.org/10.1007/s10741-019-09906-x
Fitzpatrick, L.A., Turner, R.T., Ritman, E.R. (2003). Endochondral bone formation in the heart:
A possible mechanism of coronary calcification. Endocrinology 144(6): 2214-2219
Florido, R., Smith, K.L., Cuomo, K.K., et al. (2017). Cardiotoxicity from human epidermal growth factor receptor‐2 (HER2) targeted therapies. JAHA 6(9): https://doi.org/10.1161/JAHA.117.006915
Gangwar, A., Kumar, P., Rawat, A., et al. (2014). Noninvasive measurement of systolic blood pressure in rats: A novel technique. Indian Journal of Pharmacology 46(3): 351-352.
Gibo, T., Sekiguchi, N., Gomi, D., et al. (2019). Targeted therapy with trastuzumab for epidermal growth factor receptor 2 (HER2) positive advanced salivary duct carcinoma: A case report. Molecular & Clinical Oncology 11: 111-115.
Gilbert, B.W. (1992). Inhibitors and regression of left ventricular hypertrophy. Clinical
Cardiology 15(10): 711-714.
Goda, A., Masuyama, T. (2014). Left ventricular hypertrophy as a target of treatment in patients
with hypertension. Circulation Journal 78(11): 2633-2634.
Gregory, Y.H. (2001). Regression of left ventricular hypertrophy and improved prognosis: Some
hope now….or hype? Circulation 104: 1582-1584.
Guglin, M., Krischer, J., Tamura, R., et al. (2019). Randomized trial of lisinopril vs. carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. Journal of American College of Cardiology 73(22): 2859-2868.
Gujral, D.M., Lloyd, G., Bhattacharyya, S. (2018). Effect of prophylactic beta-blocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab. Breast 37: 64-71.
Guo, S., Tse, G., Liu, T. (2020). Protective strategies to prevent trastuzumab-induced cardiotoxicity. The Lancet 395(10223): 491-492.
Hamed, R.H., Salim, K., Alzahrani, A., et al. (2016). Cardiotoxicity of the adjuvant trastuzumab
in a Saudi population: clinical experience of a single institution. Forum of Clinical Oncology 7(2): 1-6.
Hidalgo, S., Albright, C.A., Wells, G.L. (2013) A case of trastuzumab-associated cardiomyopathy presenting as an acute coronary syndrome: Acute trastuzumab cardiotoxicity. Case Reports in Cardiology 2013: 473979.
Iqbal, M., Dubey, K., Anwer, T., et al. (2008). Protective effects of telmisartan against acute
doxorubicin-induced cardiotoxicity in rats. Pharmacological Report 60: 382-390.
Janbabai, G., Nabati, M., Faghihinia, M., et al. (2017). Effect of enalapril on preventing anthracycline-induced cardiomyopathy. Cardiovascular Toxicology 17(2): 130-139; https://doi.org/10.1007/s12012-016-9365-z
Jawa, Z., Perez, R.M., Garlie, L., et al. (2016). Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis. Medicine 95(44):e5195.
Jayeola, O.C., Oyagbemi, A.A., Okunlola, I.O., et al. (2020). Effect of cocoa powder on hypertension and antioxidant status in uninephrectomized hypertensive rats. Veterinary World 13(4): 695-705.
Jones, A.L., Barlow, M., Barrett-Lee, P.J., et al. (2009). Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. British Journal of Cancer 100: 684-692.
Klein, P.M., Dybdal, N. (2003). Trastuzumab and cardiac dysfunction: update on preclinical studies. Seminars in Oncology 30(5 Suppl. 16): 49-53.
Kowalczyk, L., Bartsch, R., Singer, C.F., et al. (2017). Adverse events of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive breast cancer patients. Breast Cancer 12(6): 401-408.
Lameire, N. (2014). Nephrotoxicity of recent anti-cancer agents. Clinical Kidney Journal 7(1): 11-22.
Lemmens, K., Segers, V.F., Demolder, M., et al. (2006). Role of neuregulin-1/ErbB2 signalling
in endothelium-cardiomyocyte cross-talk. Journal of Biological Chemistry 281: 19469-19477.
Leong, D.P., Cosman, T., Alhussein, M.M., et al. (2019). Safety of continuing trastuzumab despite mild cardiotoxicity: A Phase I trial. JACC: Cardiology 1(1): 1-10.
Ma, Y-X., Bai, F., Qin, F., et al. (2019). Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials. BMC Pharmacology and Toxicology 20: 18; https://doi.org/10.1186/s40360-019-0298-6
Mandaliya, H., Baghi, P., Prawira, A., et al. (2015). A rare case of paclitaxel and/or trastuzumab induced acute hepatic necrosis. Case Reports in Oncological Medicine 2015: Article 825603; https://doi.org/10.1155/2015/825603
Manole, C.G., Marinescu, B.G., Marta, D. (2019). Areas of cartilaginous and osseous metaplasia
after experimental myocardial infarction in rats. The Anatomical Record (Hoboken) 302(6): 947-953.
Matos, L., Nzikou, J.M., Matouba, E., et al. (2009) Studies of Irvingia gabonensis seed kernel: oil technological applications. Pakistani Journal of Nutrition 8: 151-157.
Messerli, F.H., Rimoldi, S.F., Bangalore, S. (2017). The transition from hypertension to heart
failure: contemporary update. JACC: Heart Failure 5(8): 543-553.
Mohan, N., Jiang, J., Dokmanovic, M., et al. (2018). Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. Antibody Therapy 1(1): 13-17.
Munster, P., Krischer, J., Tamura, R., et al. (2019). A randomized community-based trial of an
angiotensin converting enzyme inhibitor, lisinopril or a beta blocker, carvedilol for the prevention of cardiotoxicity in patients with early stage HER2-positive breast cancer receiving adjuvant trastuzumab. Cancer Research 79(4 Suppl): Abstract GS5-01; https://doi.org/10.1158-7445.SABCS18-GS501
National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals (2011) Guide for the Care and Use of Laboratory Animals. The National Academies Press, Washington D.C., U.S.A.
Nguyen, N., Naik, V., Speer, M.Y. (2012). Diabetes mellitus accelerates cartilaginous metaplasia
and calcification in atherosclerotic vessels of LDL mutant mice. Cardiovascular Pathology 22(2): 167-175.
Olesen, L.L., Andersen, A. (2016). ECG as a first step in the detection of left ventricular systolic dysfunction in the elderly. ESC Heart Failure 3(1): 44-52.
Olesen, L.L., Andersen, A., Thaulow, S. (2015). Hand-held echocardiography is useful for diagnosis of left systolic dysfunction in an elderly population. Danish Medical Journal 62: A5100.
Olorundare, O., Adeneye, A., Akinsola, A., et al. (2020). African vegetables (Clerodendrum
volubile leaf and Irvingia gabonensis seed extracts) effectively mitigates trastuzumab-induced cardiotoxicity in Wistar rats. Oxidative Medicine and Cellular Longevity 2020: Article ID 9535426.
Olorundare, O.E., Adeneye, A.A., Akinsola, A.O., et al. (2021). Therapeutic potentials of
selected antihypertensive agents and their fixed-dose combinations against trastuzumab-mediated cardiotoxicity. Frontiers in Pharmacology (In Press).
Perez, I.E., Alam, S.T., Hernandez, G.A., et al. (2019). Cancer therapy-related cardiac dysfunction: An overview for the clinician. Clinical Medicine Insights: Cardiology 13: 1-11.
Perik, P.J., de Korte, M.A., van Veldhuisen, D.J., et al. (2007). Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Expert Review of Anticancer Therapy 7(12): 1763-1771.
Phan, D.Q., Silka, M.J., Lan, Y-T., et al. (2015). Comparison of formulas for calculation of the corrected QT interval in infants and young children. Journal of Pediatrics 166(4): 960-964.e2; https://www.doi.org/10.1016/j.jpeds.2014.12.037
Pinter, M., Kwanten, W.J., Jain, R.K. (2018). Renin-angiotensin system inhibitors to mitigate cancer treatment-related adverse events. Clinical Cancer Research 24(16): 3803-3812. https://doi.org/10.1158/1078-0432.CCR-18-0236
Piotrowski, G., Gawor, R., Stasiak, A., et al. (2012). Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study. Archives of Medical Sciences 8(2): 227-235.
Pituskin, E., Mackey, J.R., Koshman, S., et al. (2017). Multidisciplinary approach to novel
therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. Journal of Clinical Oncology 35: 870-877.
Poon, K.A., Flagella, K., Beyer, J., et al. (2013). Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability. Toxicology and Applied Pharmacology 273:298-313.
Porta, C., Cosmai, L., Gallieni, M., et al. (2015) Renal effects of targeted anticancer therapies. Nature Reviews Nephrology 11: 354-370.
Qiao, J-H., Fishbein, M.C., Demer, L.L., et al. (1995). Genetic determination of cartilaginous
metaplasia in mouse aorta. Arteriosclerosis, Thrombosis, and Vascular Biology 15: 2265-2272.
Rahib, L., Wehner, M., Matrisian, L.M., et al. (2020). Pojection of cancer incidence and death to 2040 in the US: Impact of cancer screening and a changing demographic. Journal of Clinical Oncology 38(15_suppl.): 1566.
Ruggenenti, P., Iliev, I., Costa, G.M., et al. (2008). Preventing left ventricular hypertrophy by
ACE inhibition in hypertensive patients with type 2 diabetes: A prespecified analysis of the Bergamo nephrologic diabetes complications trial (BENEDICT). Diabetes Care 31(8): 1629-1634.
Rygiel, K. (2016). Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials. Indian Journal of Pharmacology 48(5): 490-497; https://doi.org/10.4103/0253-7613.190719
Sendur, M.A., Aksoy, S., Altundag, K. (2013). Cardiotoxicity of novel HER2-targeted therapies. Current Medical Research and Opinion 29: 1015-1024.
Sharma, P., Hakimian, S., Camacho, J., et al. (2018). Prevention of Chemo-induced cardiotoxicity with beta-blockers. Journal of the American College of Cardiology 71(11 Suppl): A1803.
Siegel, R.L., Miller, K.D., Jemal, A. (2020). Cancer Statistics, 2020. CA Cancer Journal for Clinicians 70: 7-30.
Spector, N.L., Blackwell, K.L. (2009) Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology 27: 5838-5847.
Tahir, H., Bardia, N., Bath, K., et al. (2019). Trastuzumab-induced cardiomyopathy and intermittent left bundle branch block. Cardiology Research 10(4): 230-235.
Tsang, W., Moe, G. (2007). Trastuzumab and heart failure. Cardiology Rounds 8: 1-6.
Umoru, G., Taitano, M., Beshay, S., et al. (2020). Pulmonary arterial hypertension in breast cancer patients on HER2-targeted therapy: a review of FDA Adverse Events Reporting System data. ERJ Open Research 6: 00199-2020; https://www.doi.org/10.1183/23120541.00199-2020
Vaduganathan, M., Hirji, S.A., Qamar, A., et al. (2019). Efficacy of neurohormonal therapies in
preventing cardiotoxicity in patients with cancer undergoing chemotherapy. JACC Cardio-Oncology 1: 54-65.
Vejpongsa, P., Yeh, E.T.H. (2014). Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. Journal of American College of Cardiology 64: 938-945.
Wallin, R., Wajih, N., Greenwood, G.T., et al. (2001). Arterial calcification: A review of
mechanisms, animal models, and the prospects for therapy. Medicinal Research Reviews 21(4): 274-301.
Wittayanukorn, S., Qian, J., Westrick, S.C., et al. (2018). Prevention of trastuzumab and anthracycline-induced cardiotoxicity using Angiotensin-converting Enzyme inhibitors or β-blockers in older adults with breast cancer. American Journal of Clinical Oncology 41(9): 909-918.
Zablocki, D., Sadoshima, J. (2013). Angiotensin II and oxidative stress in the failing heart.
Antioxidants & Redox Signaling 19(10): 1095-1109.
التنزيلات
منشور
إصدار
القسم
الرخصة
الحقوق الفكرية (c) 2021 Nigerian Journal of Physiological Sciences
هذا العمل مرخص بموجب Creative Commons Attribution 4.0 International License.
